Condition: Non-Hodgkin's Lymphoma · Hodgkin's Disease · Leukemia, Lymphocytic, Chronic · Sponsor: Dana-Farber Cancer Institute
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.
This description comes directly from the study's public registry record.
Celeste Carey, MS · 857-215-1646 · celeste_carey@dfci.harvard.edu
Jennifer Brown, MD PhD · 617-632-4564 · Jennifer_Brown@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00131014